SoftOx Solutions (SOFTX) Stock Overview
Operates as a clinical-stage pharmaceutical company that develops antimicrobials products for infection prevention and treatment in Norway. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SOFTX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
SoftOx Solutions AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.061 |
| 52 Week High | NOK 0.17 |
| 52 Week Low | NOK 0.01 |
| Beta | 2.3 |
| 1 Month Change | -0.65% |
| 3 Month Change | -26.51% |
| 1 Year Change | 281.25% |
| 3 Year Change | -99.74% |
| 5 Year Change | -99.91% |
| Change since IPO | -99.82% |
Recent News & Updates
Shareholder Returns
| SOFTX | NO Pharmaceuticals | NO Market | |
|---|---|---|---|
| 7D | 1.7% | -1.3% | 0.5% |
| 1Y | 281.3% | 3.6% | 9.8% |
Return vs Industry: SOFTX exceeded the Norwegian Pharmaceuticals industry which returned 3.6% over the past year.
Return vs Market: SOFTX exceeded the Norwegian Market which returned 9.8% over the past year.
Price Volatility
| SOFTX volatility | |
|---|---|
| SOFTX Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in NO Market | 11.1% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: SOFTX's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: SOFTX's weekly volatility has decreased from 39% to 8% over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 2 | Thomas Bjarnsholt | soft-ox.com |
SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that develops antimicrobials products for infection prevention and treatment in Norway. The company develops SoftOx Inhalation Solution, an inhalation solution that is phase II clinical trial for the treatment of ventilator associated pneumonia and other airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi.
SoftOx Solutions AS Fundamentals Summary
| SOFTX fundamental statistics | |
|---|---|
| Market cap | NOK 145.82m |
| Earnings (TTM) | -NOK 3.00m |
| Revenue (TTM) | NOK 13.59m |
Is SOFTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOFTX income statement (TTM) | |
|---|---|
| Revenue | NOK 13.59m |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 13.59m |
| Other Expenses | NOK 16.59m |
| Earnings | -NOK 3.00m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Mar 25, 2026
| Earnings per share (EPS) | -0.0013 |
| Gross Margin | 100.00% |
| Net Profit Margin | -22.06% |
| Debt/Equity Ratio | 0% |
How did SOFTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/27 06:55 |
| End of Day Share Price | 2025/12/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SoftOx Solutions AS is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.